SCHEDULE: Lincoln Alternative Strategies Discloses 6.18% Stake in Silexion
Beneficial Ownership Disclosure
Lincoln Alternative Strategies LLC has reported a 6.18% beneficial ownership stake in Silexion Therapeutics Corp., holding 131,250 ordinary shares.
Summary
- Lincoln Alternative Strategies LLC beneficially owns 131,250 ordinary shares of Silexion Therapeutics Corp.
- This ownership represents 6.18% of Silexion Therapeutics Corp.'s outstanding ordinary shares.
- The beneficial ownership percentage is based on 2,123,892 shares of the Issuer's common stock issued and outstanding as of September 12, 2025.
- The filing was made under Rule 13d-1(c), indicating a passive investment purpose, not for changing or influencing control of the issuer.
- The reporting person's citizenship or place of organization is Delaware.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership, which is neutral in sentiment. The presence of an institutional investor can be seen as a minor positive signal, but the filing itself does not convey strong positive or negative news about the company's operations or financial performance.
Positives
- A significant institutional investor, Lincoln Alternative Strategies LLC, has disclosed a 6.18% stake, which may be viewed as a vote of confidence in Silexion Therapeutics Corp.
Risks
- No company-specific risks for Silexion Therapeutics Corp. are detailed in this beneficial ownership disclosure.
Future Outlook
This filing is a disclosure of current beneficial ownership and does not contain any forward-looking statements or guidance from Silexion Therapeutics Corp. or the reporting entity regarding future performance or strategy.
Industry Context
This filing is a standard disclosure of institutional ownership and does not provide specific industry context or competitive analysis for Silexion Therapeutics Corp. or its sector.
Stakeholder Impact
- Shareholders may view the disclosure of a significant institutional stake as a positive indicator of investor confidence in Silexion Therapeutics Corp.
Key Dates
| Date | Description |
|---|---|
| 09/12/2025 | Date of event which requires the filing of this statement, reflecting the beneficial ownership. |
| 09/15/2025 | Date the Schedule 13G statement was signed by Stephen Temes, Managing Member of Lincoln Alternative Strategies LLC. |
Keywords
Silexion Therapeutics, Lincoln Alternative Strategies, Beneficial Ownership, SEC Filing, Schedule 13G, Institutional Investment, Ordinary Shares, G1281K122
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.